Register      Login
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
Shopping Cart: ( empty )
You are here: Home > Journals > SH > SH05041
EDITORIAL
Contents Vol 3(1)

Genital herpes vaccines—cause for cautious optimism

Lewis J. Haddow A and Adrian Mindel A B
+ Author Affiliations
- Author Affiliations

A Sexually Transmitted Infections Research Centre, Marian Villa, Westmead Hospital and University of Sydney, Westmead, NSW 2145, Australia.

B Corresponding author. Email: adrianm@icpmr.wsahs.nsw.gov.au

Sexual Health 3(1) 1-4 https://doi.org/10.1071/SH05041
Submitted: 12 July 2005  Accepted: 13 September 2005   Published: 20 February 2006

Abstract

The high prevalence of herpes simplex virus infections in many communities, its numerous serious physical and psychological complications and its importance in enhancing the transmission of HIV make this virus an obvious target for prevention by vaccination. Randomised clinical trials of only one genital herpes vaccine has shown efficacy so far. Analysis of clinical results is complicated by the difference between disease and infection, different results for males and females and the interaction between HSV-1 and HSV-2 immunity.


References


[1] Simmons A. Clinical manifestations and treatment considerations of herpes simplex virus infection. J Infect Dis 2002; 186(Suppl 1): S71–7.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[2] Mindel A,  Marks C. Psychological symptoms associated with genital herpes infections. Epidemiology and approaches to management. CNS Drugs 2005; 19 303–12.
| PubMed |

[3] Weiss HA,  Buvé A,  Robinson NJ,  Van Dyck E,  Kahindo M,  Anagonou S, et al. Study group on heterogeneity of HIV epidemics in African cities. The epidemiology of HSV-2 infection and its association with HIV infection in four African populations. AIDS 2001; 15(Suppl 4): S97–108.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[4] Stanberry LR,  Cunningham AL,  Mindel A,  Scott LL,  Spruance SL,  Aoki FY, et al. Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis 2000; 30 549–66.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[5] Stanberry LR,  Spruance SL,  Cunningham AL,  Bernstein DI,  Mindel A,  Sacks S, et al. GlaxoSmithKline herpes vaccine efficacy study group. Glycoprotein-D–adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347 1652–61.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[6] Corey L,  Langenberg AG,  Ashley R,  Sekulovich RE,  Izu AE,  Douglas JM, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 1999; 282 331–40.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[7] Langenberg AG,  Corey L,  Ashley RL,  Leong WP,  Straus SE. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 1999; 341 1432–8.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[8] Langenberg A,  Benedetti J,  Jenkins J,  Ashley R,  Winter C,  Corey L. Development of clinically recognizable genital lesions among women previously identified as having “asymptomatic” herpes simplex virus type 2 infection. Ann Intern Med 1989; 110 882–7.
| PubMed |

[9] Posavad CM,  Koelle DM,  Corey L. High frequency of CD8+ cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes. J Virol 1996; 70 8165–8.
| PubMed |

[10] Mikloska Z,  Cunningham AL. Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J Gen Virol 1998; 79 353–61.
| PubMed |

[11] Wald A,  Zeh J,  Selke S,  Ashley RL,  Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995; 333 770–5.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[12] Mindel A , Taylor R , Taylor J , Marks C , Shaw J , Cunningham AL . Prevalence of infection with HSV 1 and 2 in Australia: a nationwide population-based survey. Abstract presented at 16th International Society for Sexually Transmitted Disease Research (ISSTDR) meeting, July 2005, Amsterdam, Netherlands.

[13] Vyse AJ,  Gay NJ,  Slomka MJ,  Gopal R,  Gibbs T,  Morgan-Capner P, et al. The burden of infection with HSV-1 and HSV-2 in England and Wales: implications for the changing epidemiology of genital herpes. Sex Transm Infect 2000; 76 183–7.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[14] Tran T,  Druce JD,  Catton MC,  Kelly H,  Birch CJ. Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003. Sex Transm Infect 2004; 80 277–9.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[15] Haddow LJ , Dave B , Mindel A , Chung C , Marks C , Dwyer D . Increase in rates of herpes simplex virus type 1 (HSV-1) as a cause of genital herpes between 1979 and 2003. Abstract presented at Australasian Sexual Health Conference, August 2005, Hobart, Australia.

[16] Auslander BA,  Rosenthal SL,  Succop PA,  Mills LM,  Stanberry LR,  Bernstein DI. Gender-specific predictors of genital herpes vaccine acceptance in a college population. Int J STD AIDS 2005; 16 27–30.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[17] Mays RM,  Sturm LA,  Zimet GD. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med 2004; 58 1405–13.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[18] Roberts CM,  Pfister JR,  Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003; 30 797–800.
| PubMed |

[19] Breinig MK,  Kingsley LA,  Armstrong JA,  Freeman DJ,  Ho M. Epidemiology of genital herpes in Pittsburgh: serologic, sexual, and racial correlates of apparent and inapparent herpes simplex infections. J Infect Dis 1990; 162 299–305.
| PubMed |

[20] Pebody RG,  Andrews N,  Brown D,  Gopal R,  de Melker H,  François G, et al. The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. Sex Transm Infect 2004; 80 185–91.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[21] Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004; 11(Suppl 1): 24A–35A.
| PubMed |

[22] Mikloska Z,  Bosnjak L,  Cunningham AL. Immature monocyte-derived dendritic cells are productively infected with herpes simplex virus type 1. J Virol 2001; 75 5958–64.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[23] Schacker T,  Ryncarz AJ,  Goddard J,  Diem K,  Shaughnessy M,  Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 1998; 280 61–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[24] Wald A,  Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 2002; 185 45–52.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[25] del Mar Pujades Rodriguez M,  Obasi A,  Mosha F,  Todd J,  Brown D,  Changalucha J, et al. Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. AIDS 2002; 16 451–62.
| Crossref | GoogleScholarGoogle Scholar | PubMed |

[26] Cunningham AL,  Dwyer DE. The pathogenesis underlying the interaction of HIV and herpes simplex virus after co-infection. J HIV Ther 2004; 9 9–13.
| PubMed |